MetaCap

KALA BIO (KALA) vs Propanc Biopharma (PPCB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Propanc Biopharma is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KALA+651.39%PPCB+256.93%
+1015%+451%-113%
Oct 7, 20261 yearNov 20, 2026
KALA+820.38%PPCB+266.48%
+864%+384%-96%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KALA versus PPCB key metrics
MetricKALAPPCB
Share price$2.71$1.78
Market cap$1.74M$1.87M
1-day change-10.28%+3.19%
EPS (TTM)$-321.30$-95.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-26.98M$-18.86M
52-week high$2,865.00$315.00
52-week low$2.65$1.61
Distance from 52-week high-99.91%-99.43%
Average volume52.52K188.66K
Shares outstanding644.66K1.05M
Employees62
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About KALA BIO

KALA stock →

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Propanc Biopharma

PPCB stock →

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

KALA vs PPCB FAQ

Which is bigger, KALA BIO or Propanc Biopharma?

Propanc Biopharma (PPCB) is larger, with a market capitalization of $1.87M compared with $1.74M for KALA BIO (KALA).

Are KALA BIO and Propanc Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons